Brain regional serotonin synthesis can be estimated in vivo using positron emission tomography (PET) and a- [( 11 )C]methyl-L-tryptophan ( 11 C-AMT) trapping (K*) as a proxy. Recently, we reported evidence of lower normalized 11 C-AMT trapping in the orbitofrontal cortex (OBFC) of subjects meeting the criteria for an impulsive and/or aggressive behavioral phenotype. In this study, we examined whether part of the variance in OBFC serotonin synthesis is related to polymorphisms of the gene that encodes for the indoleamine's ratelimiting enzyme in the brain, tryptophan hydroxylase-2 (TPH 2 ). In all, 46 healthy controls had PET 11 C-AMT scans and were genotyped for 11 single-nucleotide polymorphisms (SNPs) distributed across the TPH 2 gene and its 5 0 upstream region. Several TPH 2 SNPs were associated with lower normalized blood-to-brain clearance of 11 C-AMT in the OBFC. Dose-effect relationships were found for two variants (rs6582071 and rs4641527, respectively, located in the 5 0 upstream region and intron 1) that have previously been associated with suicide. Associations in the OBFC remained statistically significant in a mixed larger sample of patients and controls. These results suggest that in humans, genetic factors might partly account for variations in serotonin synthesis in the OBFC.
Introduction
Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the production of serotonin. Whereas the first TPH isoform (now called TPH 1 ) is mainly expressed in the periphery plus pineal gland, mRNA of a second isoform (TPH 2 ) is expressed exclusively in brain 5-HT neurons. 1 In the mouse brain stem, the neural expression of TPH 2 appears to be 150 times higher than TPH 1 , suggesting that TPH 2 may have a more prominent role in the brain 5-HT synthesis than TPH 1 . 1 A number of studies have found that variation in TPH 2 polymorphisms is associated with major depression, suicide, anxiety and attention deficit/hyperactivity disorder (for example, see refs. 2-8), although not always consistent (for example, see refs. 9-12) (see Supplementary Table S1 ). In healthy samples, variation in the TPH 2 promoter G/T (À703) polymorphism or variants in the intronic and/or upstream region have been associated with differences in sensitivity to stress-induced activation of the amygdala, 13 response inhibition 14 and anxiety-like temperaments. 15 Hence, although the studies are still inconclusive, genetic variation in the production of brain 5-HT may account for some of the individual differences in emotion regulation and risk for psychopathology. The TPH 2 gene is located on chromosome 12q21.1, spanning a region of approximately 93.5 kb, and consisting of 11 exons. Several studies have investigated the potential functional role of TPH 2 sequence variants (Supplementary Table S2 ). A study in inbred mice showed that the homozygous carriers of the 1473G mutation had 50-70% lower 5-HT synthesis in the frontal cortex and striatum and an approximately 40% reduction in 5-HT tissue concentrations compared with the homozygous wild-type 1473C inbred mice. 16 In humans, a mutation of G1473A (R441H), which is the human equivalent of the C1473G mutant in mice, was associated with an 80% reduction in enzyme activity when expressed in PC12 cells. 17 These results were confirmed in vivo in a study in knock-in mice, showing a 40-80% reduction in 5-HT synthesis in the striatum, frontal cortex and hippocampus. 18 However, this G1473A mutant is very rare in humans if not absent. 3, [19] [20] [21] [22] Most recent studies investigated the functional relevance of specific TPH 2 polymorphisms conducting in vitro assays. For instance, transcriptional activity of the promoter variant rs11178897, of which one of the A alleles has been shown to be protective for unipolar depression, 4 has been associated with a 22% reduction in 5-HT in both primary 5-HT neurons from the rat raphe and human small lung carcinoma cells. 23 Surprisingly, no relationship with 5-HT function was found for rs4570625, which has previously been associated with increased neural activity to stress. 13, 24 The functional significance of two non-synonymous TPH 2 single-nucleotide polymorphisms (SNPs), C74A and G223A, was demonstrated recently in rhesus monkeys, showing that the A-A haplotype has higher levels of TPH 2 mRNA, protein and intracellular levels of 5-HT in PC12 cells compared with the C-G haplotype. 25 In humans, results from a large multiple population-based study showed that a TPH 2 haplotype, primarily composed of intronic variants and associated with clinical depression, anxiety and suicidal behaviors, was moderately associated with a peripheral index of low 5-HT function, cerebrospinal fluid 5-hydroxyindoleacetic acid, in healthy volunteers. 5 The functional relevance of polymorphic variation in TPH 2 for brain 5-HT synthesis in humans, as measured in vivo, is not known.
In humans, brain regional 5-HT synthesis can be estimated in vivo by positron emission tomography (PET) and a-[(
11
)C]methyl-L-tryptophan ( 11 C-AMT), measured as the blood-to-brain clearance/trapping (K*). [26] [27] [28] [29] [30] The suitability and validity of the 11 C-AMT method has been demonstrated in both healthy and clinical populations. 26, [30] [31] [32] [33] [34] [35] [36] The aim of this was to examine in vivo whether TPH 2 genetic polymorphisms would explain part of the variance in brain 5-HT synthesis in humans using the 11 C-AMT method.
Methods

Participants
In all, 70 individuals (49 men, 21 women), including 54 with no current mental disorder (39 men/15 women), took part in the study. Participants were recruited from past and ongoing 11 C-AMT studies in healthy volunteers and patients. 30, 32, 33, 35, 36 Lifetime axis I and axis II diagnoses were examined using the Structured Interview of DSM-IV disorders (SCIDI, II). 37, 38 All participants were physically healthy, as per a standard physical exam and laboratory tests and free of current drug use as verified by a urine drug screen (Triage @ ). Three patients were receiving ongoing treatment with a selective serotonin reuptake inhibitor (one patient with obsessive-compulsive disorder, two patients with major depressive disorder). All other participants were free of psychotropic medication for at least 2 weeks. Eight subjects with no current mental disorder reported having used 3,4-methylenedioxymethamphetamine (MDMA) in the past. All participants provided written informed consent. The study was carried out in accordance with the Declaration of Helsinki, and was approved by the research ethics committee at the Montreal Neurological Institute.
We conducted two sets of analyses in this sample ( Table 1 ). The primary analyses were Statistical Parametric Mapping (SPM) and Voxel of Interest (VOI) analyses in subjects free of current axis I disorder and no lifetime MDMA use (N = 46). Secondary VOI analyses were conducted in the same sample with the addition of 16 patients and eight previous MDMA users (N = 70), to increase power and test generalizability.
Owing to technical problems, genotype data were missing for rs7963803 (one control), rs1023390 (one control, two patients/past MDMA users), rs1386496 (two patients/past MDMA users) and rs4448731 (one patient/past MDMA user). Missing data were omitted separately from analyses. Free plasma tryptophan levels were not available for two patients and one control.
Procedure PET and magnetic resonance acquisition. All participants had previously undergone a 60-min dynamic PET scan, conducted with an ECAT HR þ (CTI Molecular Imaging Inc./Siemens, Knoxville, TN, USA). Transmission scans for attenuation correction were performed using a 68 Ge/Ga source before tracer injection. Immediately after the intravenous injection of 10 mCi (370 MBq) of 11 C-AMT injected over 2 min, 60-min dynamic PET data were acquired. All images were collected and reconstructed using a threedimensional mode with an intrinsic resolution of 5 Â 5 Â 5 mm 3 full-width at half-maximum, with 26 frames, each with 128 Â 128 voxels and 63 slices and a voxel size of 2.4 Â 2 Â 2 mm 3 . Blood samples were drawn throughout the PET scan from the antecubital vein at progressively longer time intervals to obtain 11 C-AMT plasma time-activity curves. All participants also underwent highresolution magnetic resonance imaging (MRI) using a 1.5-T superconducting magnet system (Philips Gyroscan; Philips Medical Systems, Eindhoven, the Netherlands) for the purpose of PET/MRI co-registration. For each participant, the PET/MRI co-registration consisted of a rigid body transformation (three translations þ three rotations) from the MRI scan native space to the PET scan native space, using PET averaged tissue activity images obtained during the time period of 5-60 min of dynamic PET data. Images were acquired in three-dimensional, T1-weighted volumes (voxel size = 1 mm Genotyping. Genomic DNA was extracted from blood and isolated according to standard procedures. 3 In all, 11 SNPs were genotyped across the TPH 2 gene and upstream regulatory region, and selected from the available SNP database of the National Center for Biotechnology Information and the literature. 3 Genotyping was carried out using the commercially available SNAPshot method (Applied Biosystems, Foster City, CA, USA). Initial amplification of the target genomic regions was carried out. Specificity of the designed primers (Alpha DNA, Montreal, QC, Canada) to TPH 2 sequences was verified by a BLAST search using Ensembl. The generated data were analyzed using the GeneMapper software v.3.7 (Applied Biosystems), which automatically determines the sample genotypes. All laboratory procedures were performed blind to subject status.
Statistical analyses
Genotyping. Genotype frequency distribution compared with Hardy-Weinberg equilibrium was tested using the HWSIM computer program (http:// krunch.med.yale.edu/hwsim), to test differences between expected and observed distributions of the genotype data. SPM analysis. Parametric K* images of 11 C-AMT were generated 39, 40 and re-sampled into MNI305 2-mm isotropic stereotaxic space using a standard automatic algorithm. 41 The re-sampling of each participant's parametric K* image into MNI305 2-mm isotropic stereotaxic space consisted of a nine parameter affine transformation (three translations þ three rotations þ three scale factors) for the MRI scan from native space to the MNI305 2-mm isotropic stereotaxic space. This transformation was then concatenated with the inverted rigid body transformation, as described above in the PET and MR acquisition section, and finally the parametric K* image was resampled. The images were subsequently smoothed to a 14 mm resolution full-width at half-maximum using an isotropic Gaussian filter. To cancel out global effects on regional K* values, regional K* values were normalized by the mean global K* of the gray matter to 100. This normalization was achieved by dividing each participant's parametric K* image with their respective mean global K* of the gray matter, and then multiplied by 100. For each of the investigated SNP, voxel-by-voxel comparisons between genotypes were made using SPM8 (Welcome Functional Imaging Laboratory, London, UK) using proportional scaling, setting the height threshold at Pp0.001 and cluster size threshold at > 100 voxels, and including genotype as a group variable.
Although the age range is rather large, age did not correlate with normalized K* in any of the investigated VOIs (P > 0.25). Moreover, there were no age differences between the genotypes of any other investigated SNPs (P > 0.19). We therefore did not correct for atrophy or spill-over effects.
VOI analysis. Functional neuroanatomical mapping of brain structures and pathways involved in emotion (dys)regulation regularly highlights the importance of cortical (orbitofrontal cortex (OBFC)), subcortical (caudate) and limbic (hippocampus, amygdala, anterior cingulate) areas, together with inter-related connections. 42, 43 The OBFC was chosen as the first VOI given that lower 5-HT function in the OBFC is perhaps the most widely reported area in the literature in relation to emotion dysregulation, in particular in relation to inhibition dysfunction. The hippocampus was also chosen as it is among the most densely innervated limbic terminal fields of 5-HT fibers. 44 Hippocampal dysfunction(s) have been reported in aggressive behaviors 42 as well as depression. 45 Finally, the caudate was selected as one of the primary VOI given its high-density innervation in 5-HT neurons, estimated at up to 1-3 times greater than in the human frontal cortex. 44, 46 These regions have all been shown previously to be large enough to be reliably identified on each participant MRI using an automatic segmentation method. 41 Group differences in normalized K* extracted from the VOI analyses were analyzed using general linear models for multivariate analysis of variance. The VOI analyses were used as a confirmation for the SPM analyses. Cohen's d effect sizes were calculated using the G-power program. 47 
Results
Healthy control sample Genotyping frequency. Frequencies of the different polymorphic variants are displayed in Supplementary Table S3 .
The genetic distribution of the control sample was in accordance with Hardy-Weinberg equilibrium, except for rs7963803 (P < 0.001).
SPM analyses. SPM analyses found dose-response relationships for two polymorphic variants: rs4641527 and rs6582071. For rs4641527 (Figure 1) , individuals who were homozygous for the T allele had no difference in normalized K* values relative to individuals who were heterozygous. Larger differences were observed when comparing individuals with one T allele relative to those who were homozygous for the G allele, with lower normalized K* values in heterozygous individuals compared with those homozygous for the G allele in parts of the orbitofrontal cortex, including Brodmann area (BA10) as well as the dorsal anterior cingulate (BA32) (max voxels = 231, Z = 4.05, P = 0.05, uncorrected). The most pronounced difference was found between homogeneous TT and GG individuals, with lower normalized K* values for TT individuals in the orbitofrontal regions, including BA10 and 11 (max voxels = 1924, Z = 4.60, P < 0.001, family-wise error corrected). In addition, those individuals with at least one T allele (GT, TT) had lower normalized K* values compared with individuals who were homozygous for the G allele, in parts of the orbitofrontal cortex and extending to the subgenual cingulate (BA10, 11 and 25) (max voxels = 1872, Z = 4.55, P < 0.001). Interestingly, individuals who were homozygous for the T allele had higher normalized K* in the dorsal parts of the cingulate (BA32, 24) and in the premotor cortex (BA6) than GG carriers, although the effects were much smaller in the TT < GG comparison (max voxels = 548, Z = 4.21, P = 0.02, corrected).
A similar dose-effect relationship was observed for rs6582071, covering most parts of the OBFC, including BA10 and 11, and extending to parts of the cingulate (BA25) and the parahippocampal gyrus (BA34) (Figure 2 ) (AA < GA: max voxels = 70, NS; GA < GG: max voxels = 215, Z = 3.86, P = 0.06, uncorrected; AA < GG: max voxels = 1887, Z = 5.09, P < 0.001, family-wise error corrected). A two-group comparison (AA, GA < GG) showed that individuals with at least one A allele had lower normalized K* values in the superior frontal gyrus and BA25 (max voxels = 1011, Z = 3.83, P = 0.002, corrected). Normalized K* was higher in the AA genotype than in the GG genotype in the left and right premotor cortex (BA6) and in a small part of the dorsal cingulate (max voxels = 295, Z = 4.23, P = 0.03, uncorrected).
Differences in normalized K* values were also found for rs2129575 (TT, GT < GG: k = 1279, Z = 4.20, P < 0.001, corrected) in a large part of the OBFC (BA10, 11 and 47) (Supplementary Figure S1) , and for rs1386496 in the medial frontal gyrus and cingulate gyrus (TT < CT: max voxels = 318, Z = 4.35, P = 0.03, uncorrected). For rs7963803, individuals with the AA or CA genotype had lower normalized K* values relative to individuals with the CC genotype in parts of the left thalamus and the right hypothalamus (voxels = 535, Z = 3.73, P = 0.027, corrected). No differences were found for rs1386494, rs4448731, rs1023990, rs1386497, rs1843812 and rs4760747. VOI analysis. VOI analyses confirmed the exploratory SPM analyses. Comparisons of normalized K* values extracted from VOI yielded group differences in the medial OBFC predicted by TPH 2 variants rs4641527, rs2129575 and rs6582071. In addition, VOI analyses found genotype differences in rs1023990 (Table 2 and Supplementary Figures  S2-S5) . Of the four a priori determined regions, the medial OBFC was the only region where TPH 2 variants were related to normalized K* values. There were no significant differences between any of the other investigated polymorphisms.
Additional extraction and analyses of the cingulate as a VOI could not confirm the SPM analyses in this region. Exploratory examination provided no clear evidence that the effects of rs4641527 and rs6582071 on normalized K* in the medial OBFC were additive (see Supplementary section).
Since gender as well as seasonality has been shown to affect serotonin function, 48, 49 we explored the effects of seasonality and gender by adding these variables as a covariate.
There were no main effects of gender on normalized K* for any of the investigated VOIs. Normalized K* in the left caudate and right anterior cingulate was higher for participants tested in summer and spring than those tested in fall or winter (F(1, 44) = 4.14, P = 0.048 and F(1, 44) = 4.25, P = 0.045). A similar trend was seen for the right caudate (F(1, 44) = 3.07, P = 0.087). There were no effects of seasonality in the other VOIs. The effects of TPH 2 genotype on normalized K* were very similar when gender and seasonality were included as covariates.
TPH 2 polymorphisms and normalized K* in the mixed sample Like in the healthy control sample, the genetic distribution for the entire sample (Supplementary Table S4 ) was in accordance with Hardy-Weinberg equilibrium, except for rs7963803 (P < 0.001). In this larger, mixed sample, the effects of TPH 2 genotype on 11 C-AMT blood-to-brain trapping were very similar to those seen in the healthy control sample, except that significant relationships with normalized K* were now also found for rs1386494 and rs2129575 in the left medial OBFC as well as the right medial OBFC for rs6582071. Effect sizes of the analyses in the entire sample were however remarkably similar to the effect sizes found in the control group (Table 3) .
Discussion
This study found that certain TPH 2 variants were significantly associated with a lower normalized blood-to-brain 11 C-AMT trapping (K*), a proxy for the regional rate of brain 5-HT synthesis in the prefrontal-limbic regions. The findings were very similar when patients were included in the analyses. Remarkably, two main variants (rs4641527 and rs6582071), which have previously been characterized as having a role in impulse control behaviors, 3 showed an association in a dose-effect manner.
The relationship between the index of 5-HT synthesis and TPH 2 genotype was observed in a healthy sample, free of psychiatric diagnosis. This is consistent with research in knockout mice showing that genetic ablation of TPH 2 strongly reduces 5-HT synthesis in raphe neurons and its metabolite, 5-hydroxyindoleacetic acid, in all brain regions, 50, 51 but does not result in marked morphological changes or overt behavioral dysfunction. 51, 52 Whether genetic vulnerability will be expressed behaviorally may depend on other biological and environmental factors. Indeed, a recent study in rhesus monkeys showed that TPH 2 polymorphisms predict cerebrospinal fluid 5-hydroxyindoleacetic acid levels, but the relation with aggressive behaviors was moderated by early life adversity. 53 Interestingly, the effects of TPH 2 genetic variation on the index of 5-HT synthesis were markedly specific for the medial OBFC. Animal studies have shown that lower 5-HT neurotransmission in this region is specifically associated with impaired behavioral inhibition. [54] [55] [56] In humans, in vivo measurements of 5-HT neurotransmission, using PET, showed lower 5-HT function in the OBFC in individuals characterized by high impulsive aggression 32, 57 relative to controls. This study suggests that in humans, polymorphic variation of TPH 2 SNPs may account for part of the variance.
The finding that the effects of TPH 2 genotype on brain 5-HT synthesis are not uniform across brain regions is in line with studies in monozygotic twins, showing that genetic effects on brain volume or neural function vary regionally. 58, 59 The results are also consistent with post-mortem studies showing regional differences in TPH 2 expression. 60, 61 Although the exact genetic contribution of TPH 2 expression on regional brain 5-HT synthesis is not known, this study suggests that, compared with the other investigated brain regions, 5-HT synthesis in the medial OBFC is regulated to a greater extent by the TPH 2 gene and relatively less by other factors known to affect TPH 2 protein or brain 5-HT synthesis, including perinatal or postnatal stressors 62, 63 and other biological factors (for example, hormones, signaling molecules, other genes). 18, 64, 65 The validity and significance of the observations presented in this study, however, rest upon the following considerations: (1) The results rest upon the assumption that the PET measurement of regional 11 C-AMT trapping values is a valid proxy for 5-HT synthesis. When the technique was originally implemented, it had been argued that the regional trapping of 11 C-AMT might reflect blood-brain transport rather than 5-HT synthesis itself. 66 However, a number of validation studies from our research group and others, collected over more than 10 years, 27, 29, [67] [68] [69] [70] now provide a basis for the consensus view that brain regional 11 C-AMT trapping represents an acceptable index of 5-HT synthesis. Of particular interest are the findings from an independent group showing Patlak plots of 11 C-AMT in primates, with a slope significantly different from zero, providing evidence for trapping irreversibility of the tracer. 28 (2) In spite of a relatively large sample size for molecular PET studies, the sample is too small to reliably investigate interactions between specific psychiatric diagnoses or gender and TPH 2 genotype on brain 5-HT synthesis, and to investigate reliably second-or higher-order interactions between the different SNPs. (3) The TPH 2 variants investigated in this study have been previously characterized behaviorally. 3 It would be of much interest to validate and compare the results of this study further by investigating TPH 2 mRNA expression for each of the investigated SNPs postmortem and in vitro. (4) It is possible that genetic variation at other 5-HT genes may have an important role in controlling 5-HT synthesis. We have not conducted thorough studies of other 5-HT genes in relation to 5-HT synthesis, but it would be of interest to further study this in the future. (5) The observed genotype-endophenotype relationships were somewhat stronger when patients were included in the analyses. As shown in Tables 2 and 3 , a post hoc power analysis indicated that effect sizes for the entire group were very similar to those for the control group only. This indicates that the difference in results between the analysis of the entire group and the control group may have been due to lower power given the smaller sample compared with the entire sample (n = 46 vs n = 70).
Notwithstanding these limitations, this study provides the first in vivo evidence for the functional significance of variants of TPH 2 polymorphisms in the intronic and 5 0 upstream region for human 5-HT synthesis. Variation in the TPH 2 gene might account, in part, for the variance in brain 5-HT synthesis in the OBFC in humans, assessed in vivo using the PET/[
11 C]-AMT method. In combination with other biological and social risk factors, this might underlie increased susceptibility for a variety of psychopathologies in which 5-HT has a major role.
